Search research articles
Contact Us
Filters
Showing results (21-30 of 174) with videos related to
Page
of 18
Sort By:
International Journal of Technology Assessment in Health Care
|
June 1, 2005
Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies
Michael Drummond, Andrea Manca, Mark Sculpher
Pharmacoeconomics
|
September 25, 2007
A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD
Laura Bojke, Edward Hornby, Mark Sculpher, et al.
Journal of Health Services Research & Policy
|
November 14, 2008
Decision analysis for resource allocation in health care
Susan Griffin, Karl Claxton, Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 15, 2008
Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies
Marco Barbieri, Neil Hawkins, Mark Sculpher
British Medical Bulletin
|
April 6, 2007
The role of NICE technology appraisal in NHS rationing
Simon Walker, Stephen Palmer, Mark Sculpher
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
September 15, 2005
Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response
Neil Hawkins, Mark Sculpher, David Epstein
Pharmacoeconomics
|
July 4, 2025
Correction: A Framework for Using Cost‑effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
Beth Woods, Alfredo Palacios, Mark Sculpher
Pharmacoeconomics
|
December 31, 2024
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
Beth Woods, Alfredo Palacios, Mark Sculpher
Health Economics
|
February 1, 2020
Distributional cost effectiveness analysis of West Yorkshire low emission zone policies
Susan Griffin, Simon Walker, Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 27, 2017
Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions
Mark Sculpher, Karl Claxton, Steven D Pearson
Page
of 18
Search research articles
Search
Showing results (21-30 of 174) with videos related to
Sort By:
Page
of 18
International Journal of Technology Assessment in Health Care
|
June 1, 2005
Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies
Michael Drummond, Andrea Manca, Mark Sculpher
Pharmacoeconomics
|
September 25, 2007
A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD
Laura Bojke, Edward Hornby, Mark Sculpher, et al.
Journal of Health Services Research & Policy
|
November 14, 2008
Decision analysis for resource allocation in health care
Susan Griffin, Karl Claxton, Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 15, 2008
Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies
Marco Barbieri, Neil Hawkins, Mark Sculpher
British Medical Bulletin
|
April 6, 2007
The role of NICE technology appraisal in NHS rationing
Simon Walker, Stephen Palmer, Mark Sculpher
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
September 15, 2005
Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response
Neil Hawkins, Mark Sculpher, David Epstein
Pharmacoeconomics
|
July 4, 2025
Correction: A Framework for Using Cost‑effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
Beth Woods, Alfredo Palacios, Mark Sculpher
Pharmacoeconomics
|
December 31, 2024
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
Beth Woods, Alfredo Palacios, Mark Sculpher
Health Economics
|
February 1, 2020
Distributional cost effectiveness analysis of West Yorkshire low emission zone policies
Susan Griffin, Simon Walker, Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 27, 2017
Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions
Mark Sculpher, Karl Claxton, Steven D Pearson
Page
of 18